Literature DB >> 22749647

Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.

Christian Prinz1, Maria Schwarz, Ivan Ilic, Kai Thorsten Laser, Roman Lehmann, Eva-Maria Prinz, Thomas Bitter, Jürgen Vogt, Frank van Buuren, Nikola Bogunovic, Dieter Horstkotte, Lothar Faber.   

Abstract

BACKGROUND: The purpose of our study was to correlate the incidence of adequate implantable cardioverter-defibrillator (ICD) interventions in hypertrophic cardiomyopathy (HCM) patients with risk markers (RMs) for sudden cardiac death (SCD) plus myocardial fibrosis as detected by late gadolinium-enhanced cardiac magnetic resonance (LGE-CMR) imaging.
METHODS: In all, 87 patients with HCM underwent LGE-CMR imaging prior to ICD implantation, performed for secondary (n = 2; 2%) or primary SCD prophylaxis (n = 85; 98%). Fibrosis was graded with a 17-segment left ventricular model (0 = absent, 1 = point-shaped, 2 = limited to 1 left ventricular segment, 3 = involving ≥ 2 segments). During follow-up, ICD memories were read out by a physician blinded to the individual patient data.
RESULTS: The number of RMs per patient was 1.9 ± 0.8. Myocardial fibrosis was present in 78 patients (90%); 26 (30%) had a fibrosis score of 3. During follow-up (3.5 ± 2.6 [range, 0.2-11.4 years]), 15 patients had 50 appropriate ICD interventions. Episodes of atrial fibrillation were found in 28 patients. Fibrosis severity correlated with occurrence of ventricular tachycardia (Cramér's V, or φc = 0.4, P < 0.001) and atrial fibrillation (φc = 0.6, P < 0.001). On multivariate regression analysis, an independent association between myocardial fibrosis (ß = 0.6, P < 0.01) and sustained ventricular tachycardia was found.
CONCLUSIONS: In HCM patients treated with ICD implantation because of a high SCD risk by traditional RM assessment, a high rate of arrhythmic events was observed during long-term follow-up. In a cohort of patients with clinical markers for high risk of SCD, severity of myocardial fibrosis as detected by an easy LGE-CMR scoring system was associated with future arrhythmic events and appropriate ICD therapies.
Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749647     DOI: 10.1016/j.cjca.2012.05.004

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  23 in total

1.  Comparative study of CMR characteristics between arrhythmogenic right ventricular cardiomyopathy patients with/without syncope.

Authors:  Huaibing Cheng; Minjie Lu; Cuihong Hou; Xuhua Chen; Jing Wang; Li Li; Junyi Wan; Gang Yin; Jianmin Chu; Sanjay K Prasad; Shu Zhang; Jielin Pu; Shihua Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2014-07-16       Impact factor: 2.357

2.  Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists.

Authors:  Arya Aminorroaya; Ali Vasheghani-Farahani; Farzad Masoudkabir; Pegah Roayaei
Journal:  J Interv Card Electrophysiol       Date:  2020-07-25       Impact factor: 1.900

Review 3.  Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.

Authors:  Waseem Hindieh; Raymond Chan; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

4.  Early gadolinium enhancement in hypertrophic cardiomyopathy: a potential premature marker of myocardial damage.

Authors:  Eduardo Pozo; Dafne Viliani; Norma Aguirre; Pilar Agudo-Quilez; María José Olivera; Paloma Caballero; Luis Jesús Jiménez-Borreguero; Fernando Alfonso
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-09       Impact factor: 2.357

5.  Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients.

Authors:  C Langer; M Lutz; M Eden; M Lüdde; M Hohnhorst; C Gierloff; M Both; W Burchert; L Faber; D Horstkotte; N Frey; C Prinz
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-22       Impact factor: 2.357

6.  Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.

Authors:  Amelie Burghardt; Frank van Buuren; Zisis Dimitriadis; Tim Grübbel; Hubert Seggewiss; Smita Scholtz; Dieter Horstkotte; Lothar Faber
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

Review 7.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

8.  Helical distribution of hypertrophy in patients with hypertrophic cardiomyopathy: prevalence and clinical implications.

Authors:  Dafne Viliani; Eduardo Pozo; Norma Aguirre; Alberto Cecconi; María J Olivera; Paloma Caballero; Luis J Jiménez-Borreguero; Fernando Alfonso
Journal:  Int J Cardiovasc Imaging       Date:  2017-05-23       Impact factor: 2.357

Review 9.  Magnetic resonance imaging for characterizing myocardial diseases.

Authors:  Maythem Saeed; Hui Liu; Chang-Hong Liang; Mark W Wilson
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-31       Impact factor: 2.357

Review 10.  [Hypertrophic and restrictive cardiomyopathy. Differentiation by imaging].

Authors:  S Fritschi; M Prothmann; J Schulz-Menger
Journal:  Herz       Date:  2015-06       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.